Reported Sunday, HUTCHMED Unveils Innovative ATTC Platform Integrating Antibodies And Small-Molecule Inhibitors To Deliver Synergistic Anti-Tumor Activity And Improved Safety
Benzinga Newsdesk 1 year ago
News
— HUTCHMED unveils its innovative ATTC platform, potentially providing precision oncology with synergistic dual-mechanism of action —— Lead candidate HMPL-A251 harnesses a selective PI3K/PIKK inhibitor payload,
— HUTCHMED unveils its innovative ATTC platform, potentially providing precision oncology with synergistic dual-mechanism of action —
— Lead candidate HMPL-A251 harnesses a selective PI3K/PIKK inhibitor payload, demonstrating promising preclinical efficacy and safety —
— Progress in global and China trials, including FRUSICA-2, SANOVO, surufatinib's PDAC and fanregratinib's IHCC studies, advances HUTCHMED's late-stage pipeline —